Clinical Trials Logo

Miyoshi Myopathy clinical trials

View clinical trials related to Miyoshi Myopathy.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04824040 Enrolling by invitation - Dysferlinopathy Clinical Trials

Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy in the RF

DYSF-RUS
Start date: January 15, 2020
Phase:
Study type: Observational [Patient Registry]

To evaluate specific characteristics of phenotype, immune status, molecular and genetic as well as morphological characteristics of adult patients with limb-girdle muscular dystrophy R2 in various regions of the Russian Federation.

NCT ID: NCT01459302 Enrolling by invitation - Clinical trials for Amyotrophic Lateral Sclerosis

Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

Start date: January 2009
Phase:
Study type: Observational

The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular disorders. The purpose of this study is to identify additional genes that may cause or put a person at risk for either familial ALS (meaning 2 or more people in a family who have had ALS), sporadic ALS, or other forms of motor neuron disease in the hopes of improving diagnosis and treatment. As new genes are found that may be linked to ALS in families or individuals, the investigators can then further study how that gene may be contributing to the disease by studying it down to the protein and molecular level. This includes all forms of ALS, motor neuron disease and ALS with fronto-temporal dementia(ALS/FTD). We also continue to study other forms of neuromuscular disease such as Miyoshi myopathy, FSH dystrophy and other forms of muscular dystrophy by looking at the genes that may be associated with them. There have been a number of genes identified that are associated with both familial and sporadic ALS, with the SOD1, C9orf72, and FUS genes explaining the majority of the cases. However, for about 25% of families with FALS, the gene(s) are still unknown. The investigators also will continue to work with families already identified to carry one of the known genes associated with ALS.